CureVac Sues Moderna Over mRNA Vaccine Patents, Adding to COVID-19 IP Litigation Wave

German biotech company CureVac SE, now a subsidiary of BioNTech, filed a patent infringement lawsuit against Moderna in the U.S. District Court for the District of Delaware on April 24, 2026. The complaint alleges that Moderna’s COVID-19 vaccine Spikevax infringes ten CureVac patents covering messenger RNA technology, including methods for stabilizing mRNA and lipid nanoparticle formulation techniques. CureVac is seeking royalty-equivalent damages based on Spikevax’s worldwide sales. Both Reuters and Bloomberg Law reported the filing on the same day.

Asserted Patents and Technical Claims

The ten patents at issue relate to nucleoside modifications used to stabilize fragile mRNA molecules and the lipid nanoparticle delivery systems that protect mRNA during administration. Effective delivery of mRNA into cells requires chemical modifications such as pseudouridine substitutions that reduce immune-mediated degradation, together with LNP encapsulation. CureVac contends that Moderna incorporated these foundational technologies without authorization in the development, manufacture, and commercialization of Spikevax. Moderna stated that it was aware of the complaint and would defend itself vigorously.

A Widening Wave of mRNA Patent Disputes

This lawsuit is the latest in a series of patent actions targeting Moderna’s COVID-19 vaccine revenues. IAM Media reported that by April 2026, Moderna faces claims from nine separate groups of patent owners, with four new actions filed this year alone. In February 2026, BioNTech itself filed a separate patent suit in Delaware against Moderna’s next-generation vaccine mNEXSPIKE. Other companies including Alnylam Pharmaceuticals, GlaxoSmithKline, and Bayer have also asserted patents against Moderna in connection with mRNA or LNP technology used in Spikevax.

The BioNTech-CureVac Relationship

BioNTech acquired CureVac last year, bringing both the company’s mRNA patent portfolio and its ongoing disputes under the BioNTech group umbrella. BioNTech and Pfizer’s Comirnaty competes directly with Moderna’s Spikevax in the global COVID-19 vaccine market. The CureVac complaint, read alongside BioNTech’s own February 2026 action, means the BioNTech group is now pursuing at least two independent patent lawsuits against Moderna simultaneously.

Broader Questions of IP Attribution in Pandemic Technology

The proliferation of mRNA patent suits reflects a structural question about how intellectual property rights should be allocated across foundational platform technologies developed incrementally over decades. Moderna generated tens of billions of dollars in Spikevax revenue, but the underlying mRNA platform drew on research by multiple academic institutions and companies. Courts and parties are now resolving, through litigation, which contributions warrant compensation and in what amounts.

Given the complexity of the technical and damages issues, this case is likely to proceed over several years. The outcome on patent validity and infringement will carry precedential weight for mRNA licensing frameworks well beyond the COVID-19 context.